Detail for Caspofungin
Basic Information
DrugID 21
DrugName Caspofungin
DrugDetail Caspofungin (brand name Cancidas worldwide) is an antifungal drug, the first of a new class termed the echinocandins from Merck & Co., Inc. It shows activity against infections with Aspergillus and Candida, and works by inhibiting ??(1,3)-D-Glucan of the fungal cell wall. Caspofungin is administered intravenously.

http://www.drugbank.ca/drugs/DB00520

http://en.wikipedia.org/wiki/Caspofungin

Indication For the treatment of esophageal candidiasis and invasive aspergillosis in patients who are refractory to or intolerant of other therapies.

http://www.drugbank.ca/drugs/DB00520

Structure Click to see the orginal picture.
Interaction
Drug Name PMIDLink Reference
Amphotericin B Kiraz N, Dag I, Yamac M, Kiremitci A, Kasifoglu N, Akgun Y. (2009) Antifungal activity ofin combination with amphotericin B against Candida glabrata: comparison of disk diffusion, Etest, and time-kill methods. Antimicrob Agents Chemother. 53(2):788-90.
Amphotericin B Chaturvedi V, Ramani R, Andes D, Diekema DJ, Pfaller MA, Ghannoum MA, Knapp C, Lockhart SR, Ostrosky-Zeichner L, Walsh TJ, Marchillo K, Messer S, Welshenbaugh AR, Bastulli C, Iqbal N, Paetznick VL, Rodriguez J, Sein T. (2011) Multilaboratory testing of two-drug combinations of antifungals against Candida albicans, Candida glabrata, and Candida parapsilosis. Antimicrob Agents Chemother. 55(4):1543-8.
Amphotericin B Cuenca-Estrella M, Gomez-Lopez A, Buitrago MJ, Mellado E, Garcia-Effron G, Rodriguez-Tudela JL. (2006) In vitro activities of 10 combinations of antifungal agents against the multiresistant pathogen Scopulariopsis brevicaulis. Antimicrob Agents Chemother. 50(6):2248-50.
Amphotericin B Arikan S, Lozano-Chiu M, Paetznick V, Rex JH. (2002) In vitro synergy ofand amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother. 46(1):245-7.
Bafilomycin A1 Del Poeta M, Cruz MC, Cardenas ME, Perfect JR, Heitman J. (2000) Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans. Antimicrob Agents Chemother. 44(3):739-46.
Bupivacaine Rodrigues AG, Araujo R, Pina-Vaz C. (2006) Interaction of local anaesthetics with other antifungal agents against pathogenic Aspergillus. Int J Antimicrob Agents. 27(4):339-43.
Cyclic peptide 6752 Harris MR, Coote PJ. (2010) Combination ofor anidulafungin with antimicrobial peptides results in potent synergistic killing of Candida albicans and Candida glabrata in vitro. Int J Antimicrob Agents. 35(4):347-56.
Cyclic peptide GS14K4 Harris MR, Coote PJ. (2010) Combination ofor anidulafungin with antimicrobial peptides results in potent synergistic killing of Candida albicans and Candida glabrata in vitro. Int J Antimicrob Agents. 35(4):347-56.
Cyclosporine Steinbach WJ, Schell WA, Blankenship JR, Onyewu C, Heitman J, Perfect JR. (2004) In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus. Antimicrob Agents Chemother. 48(5):1664-9.
Dermaseptin S3 Harris MR, Coote PJ. (2010) Combination ofor anidulafungin with antimicrobial peptides results in potent synergistic killing of Candida albicans and Candida glabrata in vitro. Int J Antimicrob Agents. 35(4):347-56.
Flucytosine Schwarz P, Dromer F, Lortholary O, Dannaoui E. (2003) In vitro interaction of flucytosine with conventional and new antifungals against Cryptococcus neoformans clinical isolates. Antimicrob Agents Chemother. 47(10):3361-4.
Flucytosine Dannaoui E, Lortholary O, Dromer F. (2004) In vitro evaluation of double and triple combinations of antifungal drugs against Aspergillus fumigatus and Aspergillus terreus. Antimicrob Agents Chemother. 48(3):970-8.
Itraconazole Shalit I, Shadkchan Y, Samra Z, Osherov N. (2003) In vitro synergy ofand itraconazole against Aspergillus spp.: MIC versus minimal effective concentration end points. Antimicrob Agents Chemother. 47(4):1416-8.
Lidocaine Rodrigues AG, Araujo R, Pina-Vaz C. (2006) Interaction of local anaesthetics with other antifungal agents against pathogenic Aspergillus. Int J Antimicrob Agents. 27(4):339-43.
Magainin 2 Harris MR, Coote PJ. (2010) Combination ofor anidulafungin with antimicrobial peptides results in potent synergistic killing of Candida albicans and Candida glabrata in vitro. Int J Antimicrob Agents. 35(4):347-56.
Posaconazole Cuenca-Estrella M, Gomez-Lopez A, Buitrago MJ, Mellado E, Garcia-Effron G, Rodriguez-Tudela JL. (2006) In vitro activities of 10 combinations of antifungal agents against the multiresistant pathogen Scopulariopsis brevicaulis. Antimicrob Agents Chemother. 50(6):2248-50.
Posaconazole Oliveira ER, Fothergill AW, Kirkpatrick WR, Coco BJ, Patterson TF, Redding SW. (2005) In vitro interaction of posaconazole andagainst clinical isolates of Candida glabrata. Antimicrob Agents Chemother. 49(8):3544-5.
Posaconazole Guembe M, Guinea J, Pel��ez T, Torres-Narbona M, Bouza E. (2007) Synergistic effect of posaconazole andagainst clinical zygomycetes. Antimicrob Agents Chemother. 51(9):3457-8.
Ranalexin Harris MR, Coote PJ. (2010) Combination ofor anidulafungin with antimicrobial peptides results in potent synergistic killing of Candida albicans and Candida glabrata in vitro. Int J Antimicrob Agents. 35(4):347-56.
Staurosporine Markovich S, Yekutiel A, Shalit I, Shadkchan Y, Osherov N. (2004) Genomic approach to identification of mutations affectingsusceptibility in Saccharomyces cerevisiae. Antimicrob Agents Chemother. 48(10):3871-6.
Sulfamethoxazole Yekutiel A, Shalit I, Shadkchan Y, Osherov N. (2004) In vitro activity ofcombined with sulfamethoxazole against clinical isolates of Aspergillus spp. Antimicrob Agents Chemother. 48(9):3279-83.
FK506 Steinbach WJ, Schell WA, Blankenship JR, Onyewu C, Heitman J, Perfect JR. (2004) In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus. Antimicrob Agents Chemother. 48(5):1664-9.
Terbinafine Gil-Lamaignere C, M��ller FM. (2004) Differential effects of the combination ofand terbinafine against Candida albicans, Candida dubliniensis and Candida kefyr. Int J Antimicrob Agents. 23(5):520-3.
Terbinafine Cavalheiro AS, Maboni G, de Azevedo MI, Argenta JS, Pereira DI, Spader TB, Alves SH, Santurio JM. (2009) In Vitro activity of terbinafine combined withand azoles against Pythium insidiosum. Antimicrob Agents Chemother. 53(5):2136-8.
Voriconazole Stergiopoulou T, Meletiadis J, Sein T, Papaioannidou P, Tsiouris I, Roilides E, Walsh TJ. (2008) Isobolographic analysis of pharmacodynamic interactions between antifungal agents and ciprofloxacin against Candida albicans and Aspergillus fumigatus. Antimicrob Agents Chemother. 52(6):2196-204.
Voriconazole Cuenca-Estrella M, Gomez-Lopez A, Garcia-Effron G, Alcazar-Fuoli L, Mellado E, Buitrago MJ, Rodriguez-Tudela JL. (2005) Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus. Antimicrob Agents Chemother. 49(3):1232-5.
Voriconazole Kiraz N, Dag I, Yamac M, Kiremitci A, Kasifoglu N, Oz Y. (2010) Synergistic activities of three triazoles withagainst Candida glabrata isolates determined by time-kill, Etest, and disk diffusion methods. Antimicrob Agents Chemother. 54(5):2244-7.
Amphotericin B Li H, Lu Q, Wan Z, Zhang J. (2010) In vitro combined activity of amphotericin B,and voriconazole against clinical isolates of Trichosporon asahii. Int J Antimicrob Agents. 35(6):550-2.
Voriconazole Li H, Lu Q, Wan Z, Zhang J. (2010) In vitro combined activity of amphotericin B,and voriconazole against clinical isolates of Trichosporon asahii. Int J Antimicrob Agents. 35(6):550-2.
Itraconazole Shalit I., Shadkchan Y., Samra Z., Osherov N. (2003) In vitro synergy ofand itraconazole against Aspergillus spp.: MIC versus minimal effective concentration end points. Antimicrobial Agents and Chemotherapy 47:1416-1418. DOI: 10.1128/aac.47.4.1416-1418.2003.
Posaconazole Oliveira E.R., Fothergill A.W., Kirkpatrick W.R., Coco B.J., Patterson T.F., Redding S.W. (2005) In vitro interaction of posaconazole andagainst clinical isolates of Candida glabrata. Antimicrobial Agents and Chemotherapy 49:3544-3545. DOI: 10.1128/aac.49.8.3544-3545.2005.
Terbinafine Cavalheiro A.S., Maboni G., de Azevedo M.I., Argenta J.S., Pereira D.I.B., Spader T.B., Alves S.H., Santurio J.M. (2009) In Vitro Activity of Terbinafine Combined withand Azoles against Pythium insidiosum. Antimicrobial Agents and Chemotherapy 53:2136-2138. DOI: 10.1128/aac.01506-08.
Fluconazole Jansen G., Lee A.Y., Epp E., Fredette A., Surprenant J., Harcus D., Scott M., Tan E., Nishimura T., Whiteway M., Hallett M., Thomas D.Y. (2009) Chemogenomic profiling predicts antifungal synergies. Molecular Systems Biology 5. DOI: 10.1038/msb.2009.95.
Amphotericin B Franzot S.P., Casadevall A. (1997) Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro. Antimicrobial Agents and Chemotherapy 41:331-336.
Flucytosine Schwarz P., Dromer F., Lortholary O., Dannaoui E. (2003) In vitro interaction of flucytosine with conventional and new antifungals against Cryptococcus neoformans clinical isolates. Antimicrobial Agents and Chemotherapy 47:3361-3364. DOI: 10.1128/aac.47.10.3361-3364.2003
Target
TargetName References EssentialGene? Link
1,3-beta-D-glucan-UDP glucosyltransferase No
Albendazole monooxygenase No
1,3-beta-glucan synthase component FKS1 No
beta-1,3-glucan synthesis inhibitor No
PathWay
PathWay Name Path Picture
Starch and sucrose metabolism - Reference pathway (KO)